1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Paclitaxel.: new trials by email Literature Review of Paclitaxel. trials Research Report on Paclitaxel.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 203 | 2023-09-05 | 2026-07-15 |
| 9-ING-41 in Patients With Advanced Cancers 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. - Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Actuate Therapeutics Inc. | 350 | 2019-01-04 | 2026-04-03 |
Lung Neoplasms (2) · Bone Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Colorectal Neoplasms (1) · Glioma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Kidney Neoplasms (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1)
Actuate Therapeutics Inc. (1) · Phanes Therapeutics (1)
United States (2) · Belgium (1) · Canada (1) · France (1) · Netherlands (1) · Portugal (1) · Spain (1)
PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 30405781, PMID 30975030, PMID 31101621, PMID 31401903, PMID 31533931, PMID 31831767, PMID 31882719, PMID 31894292, PMID 35815408, PMID 41981308